Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Glaucoma
100%
Economic Evaluation
100%
Ocular Hypertension
100%
Synthetic Evaluation
100%
Intraocular Pressure
66%
National Institutes of Health
66%
Clinical Excellence
66%
Risk Prediction Model
44%
Treat-all
33%
Tonometer
33%
Public Preferences
33%
Visual Field
22%
Quality-adjusted Life Years
22%
Risk Threshold
22%
Monitoring Time
22%
Economic Modeling
22%
Optimal Monitoring
22%
Optic Nerve Head
11%
Central Corneal Thickness
11%
Incremental Cost-effectiveness Ratio
11%
Treatment Monitoring
11%
Parameter Estimation
11%
Measurement Variability
11%
Evaluation Model
11%
Treatment Adherence
11%
Patient Experience
11%
National Institute for Health Research
11%
Prostaglandin Analogs
11%
General Public
11%
Primary Care
11%
Willingness to Pay
11%
Long-term Benefit
11%
Low Quality Data
11%
Sensitivity Analysis
11%
Public Surveillance
11%
Risk Model
11%
Effective Monitoring
11%
Pressure Data
11%
Patient Preference
11%
Risk Stratification
11%
Assessment Programs
11%
NHS Costs
11%
Health Technology Assessment
11%
Visual Optics
11%
Tonometry
11%
Criteria Preference
11%
Initiating Treatment
11%
Intensive Monitoring
11%
Optimal Frequency
11%
Annual Monitoring
11%
Two-pathway
11%
Optic Nerve Damage
11%
Risky Driving
11%
Good Communication
11%
Existing Data
11%
Efficient Monitoring
11%
Initial Risk
11%
Discrete Event Simulation
11%
Secondary Care
11%
Economic Model
11%
Service Value
11%
Raised Intraocular Pressure
11%
Nursing and Health Professions
Glaucoma
100%
Economic Evaluation
100%
Intraocular Hypertension
100%
Intraocular Pressure
77%
Tonometer
33%
Visual Field
22%
Quality Adjusted Life Year
22%
Systematic Review
11%
Practice Guideline
11%
Cohort Analysis
11%
Primary Medical Care
11%
Incremental Cost-Effectiveness Ratio
11%
Patient Preference
11%
Patient Compliance
11%
Secondary Health Care
11%
Biomedical Technology Assessment
11%
Central Corneal Thickness
11%
Optic Nerve Lesion
11%
Prostaglandin Analogue
11%
Medicine and Dentistry
Glaucoma
100%
Ocular Hypertension
100%
Intraocular Pressure
77%
Health Care Cost
33%
Visual Field
22%
Quality Adjusted Life Year
22%
Systematic Review
11%
Cost-Effectiveness Analysis
11%
Optic Nerve
11%
Cohort Analysis
11%
Patient Compliance
11%
Eye
11%
Patient Experience
11%
Prostaglandin Derivative
11%
Optic Nerve Lesion
11%
Risk Stratification
11%
Technology Assessment
11%
Patient Preference
11%
Secondary Care
11%
Health Technology
11%
Primary Health Care
11%
Agricultural and Biological Sciences
Biennials
100%
Optic Nerve
66%
Cohort Studies
33%
Systematic Review
33%
Annuals
33%
Prostaglandin Analogue
33%